Associated Papers
Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.
Yang J et al.
Translational Lung Cancer Research, 2025
41234595 (PubMed )
Supplement: tlcr-14-10-4235-supplementary.pdf
Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in Non-Small Cell Lung Cancer.
Yi H et al.
Cancer Research and Treatment, 2024
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
35304574 (PubMed )
Supplement: 41388_2022_2263_MOESM5_ESM.xlsx › Supplementary_Table_4
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
36561320 (PubMed )
Supplement: Table3.xlsx › Sheet1
Cutaneous Lymphadenoma Is a Distinct Trichoblastoma-like Lymphoepithelial Tumor With Diffuse Androgen Receptor Immunoreactivity, Notch1 Ligand in Reed-Sternberg-like Cells, and Common EGFR Somatic Mutations.
Monteagudo C et al.
The American Journal of Surgical Pathology, 2021
High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib.
Osoegawa A et al.
Jto Clinical and Research Reports, 2021
34590037 (PubMed )
Supplement: mmc3.xlsx › LOGIK_VariantMetrics-UserFilter
An unbiased in vitro screen for activating epidermal growth factor receptor mutations.
Chakroborty D et al.
The Journal of Biological Chemistry, 2019
Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
Martín Martorell P et al.
Clinical Lung Cancer, 2017
Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing.
Jauhri M et al.
Medical Oncology (northwood, London, England), 2016
Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer.
Anoosha P et al.
Mutation Research, 2015
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
Tsao AS et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2013
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.
Foster JM et al.
World Journal of Surgical Oncology, 2010
Select a paper to view details